<DOC>
	<DOC>NCT00354666</DOC>
	<brief_summary>This study was designed to test safety aspects and effects on lung function of a new dry powder version of GSK159797 for asthmatic subjects to inhale. This will allow comparison with previous studies which have only used inhalation of the drug as a vapour.</brief_summary>
	<brief_title>Single Doses GSK159797 On Patient Safety And Lung Function In Patients With Mild To Moderate Asthma</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<criteria>Inclusion criteria: Subjects with mild to moderate stable asthma but no other lung problems. Male subjects or females who are not able to get pregnant (e.g. postmenopausal or surgically sterile). Nonsmokers. Subjects that show a measurable improvement in the function of their lungs after a single dose of salbutamol. Exclusion criteria: Any significant illness. Subjects with heart problems. Subjects who have had a cold or chest infection 24 weeks prior to the study. Subjects who take medication for their asthma, or other conditions, not compatible with the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>inhaled</keyword>
	<keyword>asthmatic subjects</keyword>
	<keyword>GSK159797</keyword>
	<keyword>safety and tolerability</keyword>
	<keyword>efficacy</keyword>
	<keyword>dry powder</keyword>
</DOC>